Hemogenyx Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Hemogenyx Pharmaceuticals sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).
Hemogenyx Pharmaceuticals: 1 sponsored US clinical trial, 1 recruiting.
Hemogenyx Pharmaceuticals sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Relapsed/Refractory Acute Myeloid Leukemia (R/R AML), with 1 trials.
Mid-pack sponsor footprint
Hemogenyx Pharmaceuticals is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Therapeutic Areas
What is open in the Hemogenyx Pharmaceuticals pipeline
1 recruiting of 1 indexed (100% open).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Hemogenyx Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Hemogenyx Pharmaceuticals sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Hemogenyx Pharmaceuticals page
1 registered trials is a research-attention snapshot, not an endorsement of Hemogenyx Pharmaceuticals or any single study.
- 1 of Hemogenyx Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) is the condition Hemogenyx Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Hemogenyx Pharmaceuticals pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.